Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Cash Flow (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Net Cash Flow for 16 consecutive years, with $24.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 8844.12% to $24.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $141.0 million through Dec 2025, up 286.07% year-over-year, with the annual reading at $141.0 million for FY2025, 286.07% up from the prior year.
  • Net Cash Flow hit $24.3 million in Q4 2025 for Ani Pharmaceuticals, down from $44.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $94.0 million in Q2 2023 to a low of -$95.0 million in Q3 2024.
  • Historically, Net Cash Flow has averaged $13.7 million across 5 years, with a median of $9.5 million in 2024.
  • Biggest five-year swings in Net Cash Flow: tumbled 1567.69% in 2022 and later surged 8844.12% in 2025.
  • Year by year, Net Cash Flow stood at $85.0 million in 2021, then crashed by 109.47% to -$8.0 million in 2022, then skyrocketed by 448.36% to $28.0 million in 2023, then crashed by 99.03% to $272000.0 in 2024, then soared by 8844.12% to $24.3 million in 2025.
  • Business Quant data shows Net Cash Flow for ANIP at $24.3 million in Q4 2025, $44.2 million in Q3 2025, and $67.2 million in Q2 2025.